"Ezetimibe" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.
| Descriptor ID |
D000069438
|
| MeSH Number(s) |
D03.383.082.301.550
|
| Concept/Terms |
Ezetimibe- Ezetimibe
- (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
- Ezetimib
SCH 58235- SCH 58235
- 58235, SCH
- SCH-58235
- SCH58235
|
Below are MeSH descriptors whose meaning is more general than "Ezetimibe".
Below are MeSH descriptors whose meaning is more specific than "Ezetimibe".
This graph shows the total number of publications written about "Ezetimibe" by people in this website by year, and whether "Ezetimibe" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 5 | 5 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 4 | 4 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 1 | 3 |
| 2016 | 5 | 3 | 8 |
| 2017 | 4 | 4 | 8 |
| 2018 | 4 | 0 | 4 |
| 2019 | 2 | 5 | 7 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ezetimibe" by people in Profiles.
-
Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase. J Lipid Res. 2017 04; 58(4):656-667.
-
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis. 2013 Dec; 231(2):371-7.
-
Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities. J Pharmacol Exp Ther. 2009 Jun; 329(3):1023-31.
-
Therapy and clinical trials. Curr Opin Lipidol. 2007 Aug; 18(4):479-81.